About Tripartite motif-containing protein 60
Tripartite motif-containing protein 60 (TRIM60) is a protein
from Homo sapiens identified by UniProt accession
Q495X7, 471 residues long.
MolForge cross-references it against 0 known binders and
6 disease associations.
Target properties
| Protein name | Tripartite motif-containing protein 60 |
|---|
| UniProt accession | Q495X7 |
|---|
| Gene | TRIM60 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 471 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (6)
Diseases linked to this target (Open Targets).
- DNA methylation · score 0.06
- Ischemic stroke · score 0.04
- ovarian carcinoma · score 0.02
- chronic obstructive pulmonary disease · score 0.01
- hepatocellular carcinoma · score 0.00
- ovarian neoplasm · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q495X7-F1 | alphafold | PREDICTED | 86.16 | — |
Amino-acid sequence (471 residues)
MEFVTALVNL QEESSCPICL EYLKDPVTIN CGHNFCRSCL SVSWKDLDDT FPCPVCRFCF PYKSFRRNPQ LRNLTEIAKQ LQIRRSKRKR QKENAMCEKH NQFLTLFCVK DLEILCTQCS FSTKHQKHYI CPIKKAASYH REILEGSLEP LRNNIERVEK VIILQGSKSV ELKKKVEYKR EEINSEFEQI RLFLQNEQEM ILRQIQDEEM NILAKLNENL VELSDYVSTL KHLLREVEGK SVQSNLELLT QAKSMHHKYQ NLKCPELFSF RLTKYGFSLP PQYSGLDRII KPFQVDVILD LNTAHPQLLV SEDRKAVRYE RKKRNICYDP RRFYVCPAVL GSQRFSSGRH YWEVEVGNKP KWILGVCQDC LLRNWQDQPS VLGGFWAIGR YMKSGYVASG PKTTQLLPVV KPSKIGIFLD YELGDLSFYN MNDRSILYTF NDCFTEAVWP YFYTGTDSEP LKICSVSDSE R
Explore Tripartite motif-containing protein 60 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets